CymitQuimica logo

CAS 128486-54-4

:

Lurosetron

Description:
Lurosetron, with the CAS number 128486-54-4, is a chemical compound that functions primarily as a selective serotonin 5-HT3 receptor antagonist. This class of compounds is known for its role in the treatment of various gastrointestinal disorders, particularly in managing nausea and vomiting associated with chemotherapy and postoperative recovery. Lurosetron exhibits high affinity for the 5-HT3 receptor, which is involved in the emetic response, thereby blocking the action of serotonin at this receptor site. Its pharmacological profile suggests that it may have a favorable side effect profile compared to other antiemetics. Additionally, Lurosetron's chemical structure includes specific functional groups that contribute to its binding properties and efficacy. As with many pharmaceuticals, its development and use are subject to rigorous clinical testing to ensure safety and effectiveness in therapeutic applications. Overall, Lurosetron represents a significant advancement in the management of nausea and vomiting, particularly in patients undergoing cancer treatment.
Formula:C17H17FN4O
InChI:InChI=1/C17H17FN4O/c1-10-13(20-9-19-10)8-22-7-6-14-15(17(22)23)11-4-3-5-12(18)16(11)21(14)2/h3-5,9H,6-8H2,1-2H3,(H,19,20)
SMILES:Cc1c(CN2CCc3c(c4cccc(c4n3C)F)C2=O)[nH]cn1
Synonyms:
  • Lurosetron [INN:BAN]
  • Unii-G694G740Zp
  • 6-fluoro-5-methyl-2-[(5-methyl-1H-imidazol-4-yl)methyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 1 products.
  • 6-Fluoro-5-Methyl-2-[(5-Methyl-1H-Imidazol-4-Yl)Methyl]-2,3,4,5-Tetrahydro-1H-Pyrido[4,3-b]Indol-1…
    Biosynth
    + Info

    6-Fluoro-5-Methyl-2-[(5-Methyl-1H-Imidazol-4-Yl)Methyl]-2,3,4,5-Tetrahydro-1H-Pyrido[4,3-b]Indol-1-One

    Controlled Product
    CAS:
    <p>6-Fluoro-5-Methyl-2-[(5-Methyl-1H-Imidazol-4-Yl)Methyl]-2,3,4,5-Tetrahydro-1H-Pyrido[4,3-b]Indol-1-One is a drug that belongs to the class of fatty acid esters. It has been shown to be effective in clinical trials for the treatment of symptoms of dry eye syndrome. 6FMETI has a low safety profile and does not cause any adverse effects in humans. The drug can be administered by intravenous injection or oral administration and has a long elimination half life of 36 hours. 6FMETI is metabolized by hydrolysis to its active form, 5FMTI, which is then conjugated with glucuronic acid or methyl glutaryl coenzyme A to form an inactive metabolite. This drug also has good pharmacokinetic properties</p>
    Formula:C17H17FN4O
    Purity:Min. 95%
    Molecular weight:312.34 g/mol

    Ref: 3D-FF102588

    ne
    To inquire